drugset / Trial / NCT01765868

A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers

NCT01765868

Phase 1 Completed 8 enrolled Portola Pharmaceuticals
NaSingle-groupOpen-labelBasic science

Summary

This is a open label, single center, single oral dose, study of PRT054021, in healthy subjects.

Timeline

Start
2007-09
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Betrixaban Small molecule 80 ug Oral
Subject Betrixaban Small molecule 80 mg Oral

Indications

No indication recorded.